New cancer clinical trial: Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Published on: November 26, 2018 at 12:00PM
Condition:   Prostate Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Enzalutamide
Sponsors:   Mark Garzotto, MD;   Merck Sharp & Dohme Corp.;   Astellas Pharma Inc
Not yet recruiting
https://ift.tt/2TTPVGa